Human IgG1 lambda1, Isotype Control
Based on 2 publication(s) in Google Scholar
Human IgG1 lambda1, Isotype Control, a human-derived antibody, is an isotype control for human IgG1λ1 antibody. Human IgG1 lambda1, Isotype Control can be used in the research of diabetes and pancreatic cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.64%
- Masse moléculaire:141.84 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Human IgG1 lambda1, Isotype Control
More-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
Activité biologique
Human IgG1 lambda1, Isotype Control (48 h before supernatant collection) can be used in macrophages as a control for the inhibitory effect of the human OLR1 blocking antibody Golocdacimab (HY-P99646) on OLR1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 141.84 kDa
-
Color Colorless to light yellow
-
SMILES
[Human IgG1 lambda1, Isotype Control]
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Diabetes reshapes pancreatic cancer-associated endothelial niche by accelerating senescence. [Abstract]2025 Sep 30;16(1):8654. PMID: 41027967
Human IgG1 lambda1, Isotype Control purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]
Pancreatic tumor samples from chow (n = 6 mice per group) and diabetic (n = 9 mice per group) KPC tumor-bearing mice treated with IgG (Human IgG1 lambda1, Isotype Control) (20 mg/kg; i.c.; once weekly for 2 weeks), bimagrumab (20 mg/kg; i.c.; once weekly for 2 weeks), or bimagrumab+metformin.
Human IgG1 lambda1, Isotype Control purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]
Bar graph showing fasting blood glucose changes in diabetic tumor-bearing mice after treatment with 2 doses of IgG (Human IgG1 lambda1, Isotype Control) (20 mg/kg; i.c.; once weekly for 2 weeks), 2 doses of bimagrumab (20 mg/kg; i.c.; once weekly for 2 weeks) alone, or 2 doses of bimagrumab combined with 7 doses of metformin (n = 9 mice per group).
Human IgG1 lambda1, Isotype Control purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]
Representative images and quantification of α-SMA staining (brown) in tumors from chow and diabetic KPC tumor-bearing mice treated with IgG (Human IgG1 lambda1, Isotype Control) (20 mg/kg; i.c.; once weekly for 2 weeks) or bimagrumab (20 mg/kg; i.c.; once weekly for 2 weeks) (n = 6 mice per group).
-
Pureté et documentation
-
Fiche technique (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)